Therapeutic agents for respiratory diseases

Details Therapeutic agents for respiratory diseases Therapeutic agents for respiratory diseases

1999-11-19

2001-10-30

Krass, Frederick (Department: 1614)

Drug, bio-affecting and body treating compositions

Plant material or plant extract of undetermined constitution...

C424S769000, C424S773000, C424S774000, C424S775000, C424S776000, C424S777000, C424S779000, C514S026000, C514S169000, C514S826000, C514S863000, C514S885000, C514S887000

Reexamination Certificate

active

06309674

ABSTRACT:

This application is a 371 of PCT/JP98/02237, filed May 21, 1998.
1. Technical Field
The therapeutic agent for respiratory disease according to this invention relates to a prophylactic or therapeutic drug for respiratory diseases, a prophylactic or therapeutic drug for allergic diseases, a prophylactic or therapeutic drug for keratosis, a prophylactic or therapeutic drug for carcinomatous pain, a health food, a performance food, a cosmetic additive and a cosmetic product, which are capable of improving the symptom of, and the predisposition to, acute and chronic respiratory diseases, such as acute bronchitis, bronchial asthma, asthmatic bronchitis, chronic bronchitis, pan bronchiolitis and bronchiectasis, allergic diseases, such as atopic dermatitis, pollinosis, allergic rhinitis and allergic conjunctivitis, and keratosis, such as psoriasis, lichen, ichthyosis, furfur, and palmoplantar keratosis without side effects and at the same time capable of lowering serum IgE level on an abnormally high level in a short period of time. After the symptom and predisposition have been improved, these agents can, even after suspension of administration, persistently lower the serum IgE level if it is still abnormally high and in addition can inhibit the recurrence of the symptom.
2. Background Art
Acute and chronic respiratory diseases such as acute bronchitis, bronchial asthma, asthmatic bronchitis, chronic bronchitis, diffuse ordinary bronchiolitis and bronchiectasis are intractable diseases. The therapy of these diseases is generally a symptomatic treatment centered around temporary control of coughing with an antitussive or, in case respiratory distress intervenes, assisted respiration with a bronchodilator, although the treatment is not rewarding in cases of severe coughing. Moreover, bronchial asthma can be regarded as allergy and anti-allergics are also used for its prevention or therapy but the efficacy of such medication is not always reliable but even in patients with remission of the symptom, suspension of the administration results in recurrence of the symptoms. Adrenocortical hormones are administered in severe cases but, despite a certain rewarding effect they provide, sometimes cause intense side effects. Moreover, those, too, are symptomatic remedies. Thus, no drug is known of which recurrence of the symptom does not occur after suspension of administration. Health foods, for instance, are also available with claims to the effect that their intake leads to improvements in the patient's predisposition and a cure of diseases or control of symptoms but their efficacy is either not steadfast or has not been medically proven.
Keratosis is a representative chronic disease in dermatology, and the patients have genetic predisposition as a backgrounding factor in many cases but the cause remains to be identified. The therapy includes a topical therapy using an urea or steroid ointment and a systemic therapy using a retinoid (vitamin A derivative). In psoriasis, phototherapy is also performed. However, the therapeutic modalities so far used for keratosis are of limited effect and further have many drawbacks, for example they are symptomatic treatments or cause strong side effects.
Therefore, there has been a long-standing demand for a prophylactic or therapeutic drug for respiratory diseases, a prophylactic or therapeutic drug for allergic diseases and a prophylactic or therapeutic drug for keratosis, which, once improvements have been obtained in the symptom or predisposition, would be free from the recurrence problem following the suspension of administration.
Carcinomatous pain is an intractable symptom, in which narcotic analgesics are commonly used, but there are many problems; with those drugs, pain can hardly be fully controlled, side effects are very severe, and repeated administration leads to an attenuation of the effect. Non-narcotic analgesics are not as problematic but are used less often because their efficacy is weak. Under the circumstances, there has been a keen demand for a prophylactic or therapeutic drug for carcinomatous pain which would be potent enough with moderate side effects and free from attenuation of efficacy in repeated administration.
Meanwhile, Smilax china Linne is a naturally growing woodbine which has heretofore been used as a folk medicine in gonorrhea, syphilis, lumbago, neuralgia, rheumatism, nocturia, uremia and common cold but its efficacy as a prophylactic or therapeutic drug for respiratory diseases, such as bronchial asthma, allergic diseases, keratosis or carcinomatous pain has not been known.
DISCLOSURE OF INVENTION
As a result of their intensive investigation, the inventors of this invention found that Smilax china Linne or a plant analogous thereto is capable of improving the symptom, and the predisposition to, acute and chronic respiratory diseases, such as acute bronchitis, bronchial asthma, asthmatic bronchitis, chronic bronchitis, pan bronchiolitis and bronchiectasis, allergic diseases, such as atopic dermatitis, pollinosis, allergic rhinitis, allergic conjunctivitis, etc. and keratosis, such as psoriasis, lichen, ichthyosis, furfur, and palmoplantar keratosis without side effects and at the same time can lower serum IgE level on an abnormally high level in a short period of time. In addition, after the symptom and predisposition have been improved, these agents can, even after suspension of administration, persistently lower the serum IgE level and in addition can inhibit the recurrence of the symptom. The plant was also found to give an immediate relief of calcinomatous pain without side effects and without attenuation of the efficacy in repeated administration. The instant invention has been developed on the basis of the above findings.
This invention, therefore, is directed to a prophylactic or therapeutic drug for respiratory diseases, a prophylactic or therapeutic drug for allergic diseases, a prophylactic or therapeutic drug for keratosis and a prophylactic or therapeutic drug for carcinomatous pain, all containing Smilax china Linne as the active ingredient.
Smilax china Linne provides the above-mentioned effects even when ingested in the form of a health or a performance food, such as foods and drinks, or used in the form of a cosmetic additive or a cosmetic preparation.
(1) Active Ingredient
Smilax china Linne, which is used in this invention, is a naturally growing woodbine and its root, leaf, stem and fruit can be utilized. Those can be dried and directly ingested in various forms, such as finely minced, moderately minced, coarsely minced, finely pulverized, moderately pulverized, coarsely pulverized and finely pulverized forms, or in the form of an extract obtained by extraction with water, an organic solvent, such as alcohol (methanol, ethanol, propanol, butanol, etc.), acetone, ethyl acetate, chloroform, dichloromethane, dioxane or ether, or a hydrous organic solvent. The extraction solvent and extraction method can be freely selected and established. The extract obtained can be used as it is, after concentration (when water, ethanol, ethanol-water or the like has been used for extraction), or dried beforehand.
The plant analogous to Smilax china Linne means a plant which contains an active principle as that of Smilax china Linne, i.e. the principle showing efficacy in respiratory diseases, allergic diseases, keratosis or carcinomatous pain, thus including Smilax rhizoma, for instance.
(2) Prophylactic or therapeutic drugs for respiratory diseases, allergic diseases, keratosis and carcinomatous pain
The active principle can be administered without particular limitation in ordinary oral dosage forms such as extracts, solutions, syrups, tablets, capsules, granules, fine granules, powders, pills, suspensions, hard plasters, ointments, lotions, infusions, and decoctions. Furthermore, it can be administered transmucosally as suppositories, inhalants or nasal drops. Moreover, one may ingest it in the form of a solution prepared by adding hot water to dried Smilax china Linne as if one would have a cup of tea. Those dosa

Affiliated with

Also associated with

Rating

Therapeutic agents for respiratory diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic agents for respiratory diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents for respiratory diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2608617